Fluoxetine

• Description:

  Fluoxetine (LY-110140 free base) is a selective serotonin reuptake inhibitor (SSRI) class used for antidepressant research.

• Product Name Alternative:

  LY-110140 (free base)

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H318, H330, H336, H373, H410

• Target:

  Autophagy; Serotonin Transporter

• Type:

  Reference compound

• Related Pathways:

  Autophagy; Neuronal Signaling

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/fluoxetine.html

• Purity:

  99.87

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  FC(C1=CC=C(OC(C2=CC=CC=C2)CCNC)C=C1)(F)F

• Molecular Formula:

  C17H18F3NO

• Molecular Weight:

  309.33

• Precautions:

  H302, H315, H318, H330, H336, H373, H410

• References & Citations:

  [1]Malberg JE, et al. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology. 2003 Sep;28 (9) :1562-71|[2]Kodama M, et al. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry. 2004 Oct 15;56 (8) :570-80.|[3]Wang JW, et al. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci. 2008 Feb 6;28 (6) :1374-84.|[4]Bymaster FP, et al. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl) . 2002 Apr;160 (4) :353-61|[5]Zhang W, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology. 2000 Sep;23 (3) :250-62.|[6]Avitsur R1. Increased symptoms of illness following prenatal stress: Can it be prevented by fluoxetine? Behav Brain Res. 2017 Jan 15;317:62-70.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Citation 01:

  Adv Sci (Weinh) . 2025 Jun 10:e01981.|Behav Brain Res. 2017 Jan 15:317:62-70.|Behav Pharmacol. 2021 Feb 1;32 (1) :62-72.|Behav Pharmacol. 2024 Jun 1;35 (4) :227-238.|Behav Pharmacol. 2025 Apr 1;36 (2-3) :127-136.|Biochem Biophys Res Commun. 2020 Feb 19;522 (4) :862-868.|Biochem Pharmacol. 2023 Nov:217:115846.|Biomedicines. 2023 Apr 26;11 (5) :1279.|Brain Behav Immun. 2021 Jul:95:142-153.|Cell Prolif. 2021 Jan;54 (1) :e12953.|Cell Rep. 2021 Nov 2;37 (5) :109957.|Chem Biodivers. 2025 Sep 24:e00918.|Chemosphere. 2019 Jun:225:378-387.|Eur J Pharmacol. 2019 Jan 15:843:260-267.|Eur J Pharmacol. 2025 Dec 15:1009:178391.|J Clin Psychopharmacol. 2021 Sep-Oct;41 (5) :525-533.|J Psychiatr Res. 2023 Oct 19:168:91-99.|J Transl Med. 2024 Aug 22;22 (1) :785.|Nat Med. 2019 Sep;25 (9) :1428-1441.|Orebro University. 2024.|Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jun 15;79 (Pt B) :258-267.|Reprod Toxicol. 2025 Jan 16:108840.|Research Square Preprint. 2023 Jun 16.|Research Square Preprint. 2023 Jun 29.|Research Square Preprint. 2024 Dec 16.|Virol J. 2024 Aug 8;21 (1) :181.|Fundam Clin Pharmacol. 2018 Aug;32 (4) :363-377.|Gut Pathog. 2025 Aug 21;17 (1) :65.|Int Immunopharmacol. 2025 May 10:158:114821.|J Neuroinflammation. 2017 Oct 30;14 (1) :210.|J Neuroinflammation. 2023 May 10;20 (1) :112.|Neuropharmacology. 2021 Feb 15;184:108410.|Neurotox Res. 2020 Dec;38 (4) :887-899.|Preprints. 2023 Dec 27.|World J Biol Psychiatry. 2024 Nov 29:1-18.

• CAS Number:

  [54910-89-3]